MX366293B - Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal. - Google Patents
Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.Info
- Publication number
- MX366293B MX366293B MX2015002285A MX2015002285A MX366293B MX 366293 B MX366293 B MX 366293B MX 2015002285 A MX2015002285 A MX 2015002285A MX 2015002285 A MX2015002285 A MX 2015002285A MX 366293 B MX366293 B MX 366293B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- compounds
- methods
- gastrointestinal tract
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a compuestos y métodos para el tratamiento de trastornos asociados con la retención de fluidos o la sobrecarga de sal, como insuficiencia cardíaca (en particular, la insuficiencia cardíaca congestiva), enfermedad renal crónica, enfermedad renal terminal, enfermedad hepática, y retención de fluidos inducida por un agonista del receptor activado por proliferadores de peroxisomas (PPAR) gamma. La presente descripción también se refiere a compuestos y métodos para el tratamiento de la hipertensión. La presente invención también se refiere a compuestos y métodos para el tratamiento de trastornos del tracto gastrointestinal, incluyendo el tratamiento o reducción del dolor asociado con trastornos del tracto gastrointestinal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261691635P | 2012-08-21 | 2012-08-21 | |
PCT/GB2013/052192 WO2014029983A1 (en) | 2012-08-21 | 2013-08-20 | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015002285A MX2015002285A (es) | 2015-08-14 |
MX366293B true MX366293B (es) | 2019-07-04 |
Family
ID=49083709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015002285A MX366293B (es) | 2012-08-21 | 2013-08-20 | Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20150336892A1 (es) |
EP (1) | EP2887964B1 (es) |
JP (1) | JP6392754B2 (es) |
KR (1) | KR102138390B1 (es) |
CN (1) | CN104902930A (es) |
AU (3) | AU2013304812B2 (es) |
BR (1) | BR112015003527A2 (es) |
CA (1) | CA2880338A1 (es) |
HK (1) | HK1211469A1 (es) |
MX (1) | MX366293B (es) |
RU (1) | RU2015107019A (es) |
WO (1) | WO2014029983A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012006473A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP2590656B1 (en) | 2010-07-07 | 2017-11-15 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
JP5827328B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス,インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
WO2012006474A2 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
CA2909169A1 (en) | 2013-04-12 | 2014-10-16 | Ardelyx, Inc. | Nhe3-binding compounds and methods for inhibiting phosphate transport |
US10098959B2 (en) | 2014-05-01 | 2018-10-16 | Ionis Pharmaceuticals, Inc. | Method for synthesis of reactive conjugate clusters |
RS58378B1 (sr) | 2014-07-25 | 2019-04-30 | Taisho Pharmaceutical Co Ltd | Fenil tetrahidroizokvinolinsko jedinjenje supstituisano heteroarilom |
MX2019008171A (es) | 2017-01-09 | 2020-02-05 | Ardelyx Inc | Inhibidores del antiporte mediado por nhe. |
UA126283C2 (uk) * | 2017-01-09 | 2022-09-14 | Арделікс, Інк. | Сполуки, придатні для лікування розладів шлунково-кишкового тракту |
EP4397366A2 (en) | 2017-08-04 | 2024-07-10 | Ardelyx, Inc. | Glycyrrhetinic acid derivatives for treating hyperkalemia |
BR112020002674A2 (pt) | 2017-08-07 | 2020-07-28 | Joint Stock Company Biocad | compostos heterocíclicos inovadores como inibidores de cdk8/19 |
CA3129233A1 (en) | 2019-02-07 | 2020-08-13 | Ardelyx, Inc. | Glycyrrhetinic acid derivatives for use in treating hyperkalemia |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3926891A (en) | 1974-03-13 | 1975-12-16 | Dow Chemical Co | Method for making a crosslinkable aqueous solution which is useful to form soft, water-swellable polyacrylate articles |
US3997484A (en) | 1974-04-03 | 1976-12-14 | The United States Of America As Represented By The Secretary Of Agriculture | Highly-absorbent starch-containing polymeric compositions |
US3935099A (en) | 1974-04-03 | 1976-01-27 | The United States Of America As Represented By The Secretary Of Agriculture | Method of reducing water content of emulsions, suspensions, and dispersions with highly absorbent starch-containing polymeric compositions |
US4090013A (en) | 1975-03-07 | 1978-05-16 | National Starch And Chemical Corp. | Absorbent composition of matter |
JPS51125468A (en) | 1975-03-27 | 1976-11-01 | Sanyo Chem Ind Ltd | Method of preparing resins of high water absorbency |
JPS5346389A (en) | 1976-10-07 | 1978-04-25 | Kao Corp | Preparation of self-crosslinking polymer of acrylic alkali metal salt |
US4190562A (en) | 1977-04-04 | 1980-02-26 | The B. F. Goodrich Company | Improved water absorbent copolymers of copolymerizable carboxylic acids and acrylic or methacrylic esters |
US4470975A (en) | 1977-10-21 | 1984-09-11 | The Johns Hopkins University | Method and composition for the elimination of water from an animal body |
US4286082A (en) | 1979-04-06 | 1981-08-25 | Nippon Shokubai Kagaku Kogyo & Co., Ltd. | Absorbent resin composition and process for producing same |
JPS6025045B2 (ja) | 1980-03-19 | 1985-06-15 | 製鉄化学工業株式会社 | 塩水吸収能のすぐれたアクリル酸重合体の製造方法 |
JPS57158209A (en) | 1981-03-25 | 1982-09-30 | Kao Corp | Production of bead-form highly water-absorbing polymer |
JPS5832607A (ja) | 1981-08-20 | 1983-02-25 | Kao Corp | 吸水性に優れた吸水材料の製造法 |
US4985518A (en) | 1981-10-26 | 1991-01-15 | American Colloid Company | Process for preparing water-absorbing resins |
JPS6187702A (ja) | 1984-10-05 | 1986-05-06 | Seitetsu Kagaku Co Ltd | 吸水性樹脂の製造方法 |
US4708997A (en) | 1985-07-22 | 1987-11-24 | The Dow Chemical Company | Suspending agent for the suspension polymerization of water-soluble monomers |
US4806532A (en) | 1985-10-08 | 1989-02-21 | Mayo Foundation For Medical Education And Research | Inhibition of epithelial phosphate transport |
DE3544770A1 (de) | 1985-12-18 | 1987-06-19 | Stockhausen Chem Fab Gmbh | Verfahren und vorrichtung zum kontinuierlichen herstellen von polymerisaten und copolymerisaten der acrylsaeure und/oder methacrylsaeure |
US4766004A (en) | 1986-12-19 | 1988-08-23 | Warner-Lambert Company | Crunchy, highly palatable, bulk-increasing, dietary fiber supplement composition |
IT1217123B (it) | 1987-02-05 | 1990-03-14 | Rotta Research Lab | Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
US4999200A (en) | 1987-12-09 | 1991-03-12 | Marion Laboratories | Psyllium tablet composition, method of manufacture and method of use |
US5149541A (en) | 1988-10-03 | 1992-09-22 | The Procter & Gamble Company | Psyllium-containing produces with a distribution of particle size |
US5145906A (en) | 1989-09-28 | 1992-09-08 | Hoechst Celanese Corporation | Super-absorbent polymer having improved absorbency properties |
US5126150A (en) | 1990-10-01 | 1992-06-30 | The Procter & Gamble Company | Compositions containing psyllium |
HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
FR2674849B1 (fr) | 1991-04-02 | 1994-12-23 | Logeais Labor Jacques | Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique. |
US5140102A (en) | 1991-09-23 | 1992-08-18 | Monsanto Company | Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase |
CA2151741C (en) | 1991-12-30 | 2001-12-11 | Alan Justice | Methods of producing analgesia and enhancing opiate analgesia |
US5824645A (en) | 1991-12-30 | 1998-10-20 | Neurex Corporation | Method of treating inflammation |
US5969097A (en) | 1992-06-23 | 1999-10-19 | G. D. Searle & Co. | Human guanylin |
DK0612723T3 (da) | 1993-02-20 | 1998-03-30 | Hoechst Ag | Substituerede benzoylguanidiner, fremgangsmåde til fremstilling, deres anvendelse som lægemiddel, som inhibitor af den cellulære Na+/H+-udbytning eller som diagnostikum samt lægemiddel med indhold deraf |
US5629377A (en) | 1993-03-10 | 1997-05-13 | The Dow Chemical Company | Water absorbent resin particles of crosslinked carboxyl containing polymers and method of preparation |
IL109570A0 (en) | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
US5489670A (en) | 1993-10-29 | 1996-02-06 | G. D. Searle & Co. | Human uroguanylin |
US5610145A (en) | 1994-04-15 | 1997-03-11 | Warner-Lambert Company | Tachykinin antagonists |
US5650222A (en) | 1995-01-10 | 1997-07-22 | The Procter & Gamble Company | Absorbent foam materials for aqueous fluids made from high internal phase emulsions having very high water-to-oil ratios |
DE19518796A1 (de) | 1995-05-22 | 1996-11-28 | Hoechst Ag | Fluorphenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DK1336409T3 (da) | 1995-06-27 | 2007-08-13 | Eisai R&D Man Co Ltd | Sammensætninger af formuleringer til fremstilling af analgesimidler og til hæmning af fremadskridende neuropatiske smertelidelser |
US6054429A (en) | 1996-03-08 | 2000-04-25 | Elan Pharmaceuticals, Inc. | Epidural method of producing analgesia |
US5795864A (en) | 1995-06-27 | 1998-08-18 | Neurex Corporation | Stable omega conopetide formulations |
US5550167A (en) | 1995-08-30 | 1996-08-27 | The Procter & Gamble Company | Absorbent foams made from high internal phase emulsions useful for acquiring aqueous fluids |
GB9524104D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
EP0876347B1 (en) | 1995-11-24 | 2005-03-02 | GlaxoSmithKline S.p.A. | Quinoline derivatives |
DE19548812A1 (de) | 1995-12-27 | 1997-07-03 | Hoechst Ag | Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation |
DE19633966A1 (de) | 1996-08-22 | 1998-02-26 | Hoechst Ag | Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
AU4176997A (en) | 1996-09-16 | 1998-04-02 | Warner-Lambert Company | 3-alkyl-3-phenyl-piperidines |
AU6823098A (en) | 1997-02-28 | 1998-09-18 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists |
NZ329807A (en) | 1997-04-23 | 2000-07-28 | Pfizer | NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome |
KR100219918B1 (ko) | 1997-07-03 | 1999-09-01 | 김윤 | 대장선택적 약물전달용 조성물 |
US20010006972A1 (en) | 1998-04-21 | 2001-07-05 | Stephen A. Williams | Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome |
KR20000011247A (ko) | 1998-07-23 | 2000-02-25 | 김윤 | 다당류를이용한대장선택성약물전달조성물및약학제제 |
EP1175425A2 (en) | 1999-01-21 | 2002-01-30 | The Board Of Regents, The University Of Texas System | Inhibitors of intestinal apical membrane na/phosphate co-transportation |
US6624150B2 (en) | 1999-02-26 | 2003-09-23 | Inspire Pharmaceuticals, Inc. | Method of treating gastrointestinal tract disease with purinergic receptor agonists |
US6287609B1 (en) | 1999-06-09 | 2001-09-11 | Wisconsin Alumni Research Foundation | Unfermented gel fraction from psyllium seed husks |
JP2004513870A (ja) | 1999-07-19 | 2004-05-13 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | ナトリウムチャネルブロッカーの結合物及びその使用法 |
CO5190714A1 (es) | 1999-07-20 | 2002-08-29 | Smithkline Beecham Corp | Inhibidores del transporte de fosfato |
US6107356A (en) | 1999-08-23 | 2000-08-22 | The Procter & Gamble Company | High suction polymeric foam materials |
SE9903291D0 (sv) | 1999-09-15 | 1999-09-15 | Astra Ab | New process |
DE19945302A1 (de) | 1999-09-22 | 2001-03-29 | Merck Patent Gmbh | Biphenylderivate als NHE-3-Inhibitoren |
US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
EP1225897B1 (en) | 1999-11-01 | 2004-09-08 | RHODES, John | Composition for treatment of constipation and irritable bowel syndrome |
AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
WO2001064212A1 (en) | 2000-03-01 | 2001-09-07 | University College London | Modulators of the endocannabinoid uptake and of the vallinoid receptors |
DE10015248A1 (de) | 2000-03-28 | 2001-10-04 | Merck Patent Gmbh | Bisamidino-Verbindungen als NHE-3 Inhibitoren |
DE10019062A1 (de) | 2000-04-18 | 2001-10-25 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren |
AU2001259354A1 (en) | 2000-05-02 | 2001-11-12 | Smith Kline Beecham Corporation | Phosphate transport inhibitors |
KR20020093983A (ko) | 2000-05-12 | 2002-12-16 | 스미스클라인 비참 코포레이션 | 포스페이트 수송 억제제 |
US6414016B1 (en) | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
DE10043667A1 (de) | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline |
DE10046993A1 (de) | 2000-09-22 | 2002-04-11 | Aventis Pharma Gmbh | Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament |
AU2002213048A1 (en) | 2000-10-05 | 2002-04-15 | Smith Kline Beecham Corporation | Phosphate transport inhibitors |
JP2004517066A (ja) | 2000-11-20 | 2004-06-10 | ダウ グローバル テクノロジーズ インコーポレイティド | 水吸収性ポリマーの生体内での使用 |
DE10063294A1 (de) | 2000-12-19 | 2002-07-04 | Aventis Pharma Gmbh | Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
CA2795396C (en) | 2001-03-29 | 2015-11-17 | Synergy Pharmaceuticals, Inc. | Guanylate cyclase receptor agonists for stimulating water transport in the gastrointestinal tract to treat tissue inflammation |
US6736705B2 (en) | 2001-04-27 | 2004-05-18 | Hitachi Global Storage Technologies | Polishing process for glass or ceramic disks used in disk drive data storage devices |
MY134211A (en) | 2001-05-18 | 2007-11-30 | Smithkline Beecham Corp | Novel use |
JP2007131532A (ja) | 2001-09-28 | 2007-05-31 | Kirin Brewery Co Ltd | 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬 |
FR2830451B1 (fr) | 2001-10-09 | 2004-04-30 | Inst Nat Sante Rech Med | Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur |
US6911453B2 (en) | 2001-12-05 | 2005-06-28 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them |
AU2002354410A1 (en) | 2001-12-05 | 2003-06-17 | Japan Tobacco Inc. | Triazole compound and medicinal use thereof |
DE10161767A1 (de) | 2001-12-15 | 2003-06-26 | Merck Patent Gmbh | 2-Guanidino-4-heterocyclyl-chinazoline |
EP1321142A1 (en) | 2001-12-21 | 2003-06-25 | Novartis AG | Solid pharmaceutical composition for oral administration of Tegaserod |
US6703405B2 (en) | 2001-12-22 | 2004-03-09 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them |
DE10163992A1 (de) | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | 4-Aryl-chinazoline |
US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
AU2003225837B2 (en) | 2002-03-15 | 2008-11-06 | Forest Laboratories Holdings Limited | NE and 5-HT reuptake inhibitors for treating visceral pain syndromes |
DE60307799T2 (de) | 2002-03-19 | 2007-08-16 | Genzyme Corp., Cambridge | Hemmer des phosphattransports |
BR0309969A (pt) | 2002-05-17 | 2005-04-26 | Merck Patent Gmbh | Uso de compostos que são eficazes como moduladores de receptores seletivos de opiáceos |
US7014862B2 (en) | 2002-05-20 | 2006-03-21 | The Procter & Gamble Company | Chewable compositions containing a gel-forming extract of psyllium |
US6923466B2 (en) | 2002-12-17 | 2005-08-02 | James Tsai | Collapsible handcart capable of extending the area of carrier by operating handle |
US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20050054705A1 (en) | 2003-02-04 | 2005-03-10 | Aventis Pharma Deutschland Gmbh | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them |
US7026303B2 (en) | 2003-02-18 | 2006-04-11 | The Procter & Gamble Company | Compositions comprising a polysaccharide component and one or more coating layers |
WO2004085448A2 (en) | 2003-03-19 | 2004-10-07 | Genzyme Corporation | Unsaturated phosphinyl-phosphonate phosphate transport inhibitors |
WO2004085382A1 (ja) | 2003-03-27 | 2004-10-07 | Kirin Beer Kabushiki Kaisha | 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬 |
US20050244367A1 (en) | 2004-05-03 | 2005-11-03 | Ilypsa, Inc. | Phospholipase inhibitors localized in the gastrointestinal lumen |
JP2008500285A (ja) | 2004-05-14 | 2008-01-10 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 塩ホメオスタシス及び/又は水分ホメオスタシスに伴う疾患のための治療薬及び診断薬としての、プロウログアニリン、及びそれに由来する合成類似体又はタンパク質分解切断産物 |
DE102004046492A1 (de) | 2004-09-23 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
DE102004054847A1 (de) | 2004-11-13 | 2006-05-24 | Sanofi-Aventis Deutschland Gmbh | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE102005044817A1 (de) | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
MX2008005666A (es) | 2005-11-03 | 2009-03-02 | Ilypsa Inc | Compuestos multivalentes de indol y uso de los mismos como inhibidores de fosfolipasa-a2. |
EP1951315A2 (en) | 2005-11-03 | 2008-08-06 | Ilypsa, Inc. | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors |
US20120283411A9 (en) | 2006-06-29 | 2012-11-08 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US8779090B2 (en) | 2007-02-26 | 2014-07-15 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of heart failure and other disorders |
US20100015072A1 (en) * | 2008-06-30 | 2010-01-21 | Christopher Polla | Topical Compositions Comprising Isonicotinamide |
AU2009289846B2 (en) * | 2008-09-02 | 2014-10-16 | Sanofi-Aventis | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof |
JP5502106B2 (ja) * | 2008-12-31 | 2014-05-28 | アーデリクス,インコーポレーテッド | 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるnhe媒介性アンチポートを阻害するための組成物および方法 |
-
2013
- 2013-08-20 CA CA2880338A patent/CA2880338A1/en not_active Abandoned
- 2013-08-20 MX MX2015002285A patent/MX366293B/es active IP Right Grant
- 2013-08-20 JP JP2015527965A patent/JP6392754B2/ja active Active
- 2013-08-20 WO PCT/GB2013/052192 patent/WO2014029983A1/en active Application Filing
- 2013-08-20 KR KR1020157006558A patent/KR102138390B1/ko active IP Right Grant
- 2013-08-20 AU AU2013304812A patent/AU2013304812B2/en active Active
- 2013-08-20 CN CN201380054631.5A patent/CN104902930A/zh active Pending
- 2013-08-20 RU RU2015107019A patent/RU2015107019A/ru not_active Application Discontinuation
- 2013-08-20 US US14/421,451 patent/US20150336892A1/en not_active Abandoned
- 2013-08-20 EP EP13753904.5A patent/EP2887964B1/en active Active
- 2013-08-20 BR BR112015003527A patent/BR112015003527A2/pt not_active Application Discontinuation
-
2015
- 2015-12-11 HK HK15112247.9A patent/HK1211469A1/xx unknown
-
2016
- 2016-09-08 AU AU2016225876A patent/AU2016225876A1/en not_active Abandoned
-
2018
- 2018-05-29 AU AU2018203754A patent/AU2018203754A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2014029983A1 (en) | 2014-02-27 |
AU2016225876A1 (en) | 2016-09-29 |
AU2018203754A1 (en) | 2018-06-21 |
HK1211469A1 (en) | 2016-05-27 |
CN104902930A (zh) | 2015-09-09 |
AU2013304812A1 (en) | 2015-02-05 |
RU2015107019A (ru) | 2016-10-10 |
CA2880338A1 (en) | 2014-02-27 |
US20150336892A1 (en) | 2015-11-26 |
KR20150073949A (ko) | 2015-07-01 |
JP2015527355A (ja) | 2015-09-17 |
EP2887964A1 (en) | 2015-07-01 |
AU2013304812B2 (en) | 2016-06-09 |
MX2015002285A (es) | 2015-08-14 |
JP6392754B2 (ja) | 2018-09-19 |
KR102138390B1 (ko) | 2020-07-27 |
BR112015003527A2 (pt) | 2017-07-04 |
EP2887964B1 (en) | 2019-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016219612A1 (en) | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | |
MX366293B (es) | Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal. | |
MX2019008170A (es) | Compuestos útiles para tratar transtornos del tracto gastrointestinal. | |
MX2019008171A (es) | Inhibidores del antiporte mediado por nhe. | |
PH12015502275A1 (en) | Therapuetic uses of empagliflozin | |
EA201500997A1 (ru) | Терапевтические применения эмпаглифлозина | |
EA201790765A1 (ru) | Производные спиродиамина в качестве ингибиторов альдостерон-синтазы | |
EA033286B1 (ru) | Способ лечения или отсрочки развития хронической болезни почек | |
EA201270767A1 (ru) | Терапия на основе лигандов хемосенсорных рецепторов | |
MY170713A (en) | Treatment protocol of diabetes type 2 | |
EA201101138A1 (ru) | Соединение с конденсированным кольцом и его применение | |
MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
WO2012027482A3 (en) | Compounds, compositions and methods related to ppar antagonists | |
MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
MX2015013066A (es) | Usos terapéuticos para anticuerpos contra vegfr1. | |
BR112013012212A2 (pt) | método para tratar doença renal crônica ou doenças degenerativas relacionadas à idade do paciente | |
WO2015138532A3 (en) | Methods for the treatment of kidney fibrosis | |
WO2013185048A3 (en) | Heterocyclic guanidine f1f0-atpase inhibitors | |
MX2017000635A (es) | Inhibidores del canal de potasio medular externo renal. | |
UA108494C2 (uk) | Застосування (rs)-s-цикропропіл-s-(4-{[4-{[(1r,2r)-2-гідрокси-1-метилпропіл]окси}-5-(трифторметил)піримідин-2-іл]аміно}феніл)сульфоксіміду для лікування пухлин | |
MX2017000634A (es) | Inhibidores del canal de potasio medularmente externo renal. | |
MX2016003065A (es) | Sales de mandelato de atrasentan para el tratamiento de enfermedades renales. | |
MX2017005884A (es) | Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos. | |
CA2947310C (en) | Microparticles for treating renal cell carcinoma | |
TN2017000408A1 (en) | Treatment of type 2 diabetes mellitus patients. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |